AOTI Future Growth
Future criteria checks 4/6
AOTI is forecast to grow earnings and revenue by 48.6% and 15.1% per annum respectively. EPS is expected to grow by 46.3% per annum. Return on equity is forecast to be 17.2% in 3 years.
Key information
48.6%
Earnings growth rate
46.32%
EPS growth rate
| Medical Equipment earnings growth | 18.9% |
| Revenue growth rate | 15.1% |
| Future return on equity | 17.20% |
| Analyst coverage | Low |
| Last updated | 27 Jul 2026 |
Recent future growth updates
Recent updates
AOTI: Medicare Coverage Progress Is Expected To Unlock Wider Wound Care Adoption
Analysts have lifted their price target on AOTI from £0.97 to £1.14, reflecting updated views on fair value supported by adjustments to discount rate assumptions, revenue growth expectations, profit margin forecasts, and future P/E estimates. What’s in the News for AOTI AOTI announced that the Centers for Medicare & Medicaid Services issued a proposed Local Coverage Determination for topical oxygen therapy for diabetic foot ulcers that do not heal after four weeks of optimized care, covering the whole of the US.
AOTI: US Coverage Progress And Wound Data Will Guide Measured Re-Rating
Analysts have updated their price target for AOTI to £1.06 from £0.86, citing refreshed assumptions on discount rates, revenue growth, profit margins and future P/E levels. What’s in the News for AOTI Centers for Medicare & Medicaid Services (CMS) issued a proposed Local Coverage Determination (LCD) indicating that topical oxygen therapy is considered reasonable and necessary for diabetic foot ulcers that do not heal after four consecutive weeks of optimized care, with applicability across the entire US.Medicare Access And Home Care Trends Will Transform This Chronic Wound Therapy Opportunity
Catalysts About AOTI AOTI focuses on treating hard to heal chronic wounds through its TWO2 topical wound oxygen therapy delivered to patients at home. What are the underlying business or industry changes driving this perspective?AOTI: Real World Wound Healing Data Will Underpin Future Share Re-Rating
Analysts have modestly raised their fair value estimate for AOTI from £0.74 to £0.86, citing updated assumptions on the discount rate, revenue growth, profit margins and future P/E as the key drivers of this revised price target. What's in the News AOTI reports findings from a large multicentre retrospective cohort study published in the Journal of Vascular Surgery Vascular Insights on its Topical Wound Oxygen (TWO2) therapy, focusing on chronic lower extremity wounds.We Think That There Are Issues Underlying AOTI's (LON:AOTI) Earnings
Unsurprisingly, AOTI, Inc.'s ( LON:AOTI ) stock price was strong on the back of its healthy earnings report. However...Broader CMS Coverage And Home Care Trends Will Reshape This Chronic Wound Therapy Business
Catalysts About AOTI AOTI provides topical wound oxygen therapy and at home care services aimed at healing hard to heal chronic wounds. What are the underlying business or industry changes driving this perspective?AOTI's (LON:AOTI) Solid Profits Have Weak Fundamentals
Last week's profit announcement from AOTI, Inc. ( LON:AOTI ) was underwhelming for investors, despite headline numbers...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 104 | 8 | 10 | 11 | 2 |
| 12/31/2027 | 85 | 4 | 6 | 9 | 2 |
| 12/31/2026 | 73 | 1 | 1 | 4 | 2 |
| 12/31/2025 | 67 | 3 | -7 | -5 | N/A |
| 9/30/2025 | 65 | 3 | -9 | -7 | N/A |
| 6/30/2025 | 64 | 2 | -11 | -8 | N/A |
| 3/31/2025 | 61 | 0 | -9 | -7 | N/A |
| 12/31/2024 | 58 | -2 | -8 | -6 | N/A |
| 9/30/2024 | 54 | -6 | -6 | -4 | N/A |
| 6/30/2024 | 49 | -9 | -4 | -2 | N/A |
| 3/31/2024 | 47 | -9 | -3 | -2 | N/A |
| 12/31/2023 | 44 | -8 | -3 | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AOTI's forecast earnings growth (48.6% per year) is above the savings rate (3.6%).
Earnings vs Market: AOTI's earnings (48.6% per year) are forecast to grow faster than the UK market (11.6% per year).
High Growth Earnings: AOTI's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: AOTI's revenue (15.1% per year) is forecast to grow faster than the UK market (4% per year).
High Growth Revenue: AOTI's revenue (15.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: AOTI's Return on Equity is forecast to be low in 3 years time (17.2%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/18 10:46 |
| End of Day Share Price | 2026/08/18 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
AOTI, Inc. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Julie Simmonds | Panmure Liberum |
| Charles Hall | Peel Hunt LLP |
| Miles Dixon | Peel Hunt LLP |